Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modified vaccinia ankara virus variant

A vaccinia virus and virus technology, applied in the direction of virus/bacteriophage, virus, virus peptide, etc., can solve the problems of absolute safety, doubts about the loss of replication competitiveness, etc.

Inactive Publication Date: 2004-02-18
BAVARIAN NORDIC AS
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above findings that MVA does not completely lose its replication competitiveness in human and mammalian cells raise questions about the absolute safety of MVA as a vaccine for human use or as a vector for recombinant vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified vaccinia ankara virus variant
  • Modified vaccinia ankara virus variant
  • Modified vaccinia ankara virus variant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] As shown in detail in Example 1 and Table 1, the viruses of the present invention are unable to reproduce reproductively in the cell lines 143B, HeLa or HaCat. The specific virus strains used in the examples of the present invention have been deposited in the European Collection of Cell Cultures with the accession number V00083008. This strain is referred to throughout the specification as "MVA-BN".

[0015] Known MVA strains showed residual replication in at least one of the human cell lines tested (Figure 1, Example 1). All known vaccinia virus strains show at least partial replication in the cell line HaCat, whereas the MVA virus strains of the present invention, especially MVA-BN, do not reproduce reproductively in HaCat cells. More specifically, MVA-BN showed an expansion ratio of 0.05-0.2 in the human embryonic kidney cell line 293 (ECACC 85120602). In the human bone osteosarcoma cell line 143B (ECACC 91112502), the expansion ratio was 0.0-0.6. In the human cer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an attenuated virus derived from a modified vaccinia Ankara virus characterized by loss of the ability to replicate repeatedly in human cell lines. The present invention further describes recombinant viruses derived from the virus and the use of the virus or recombinants thereof as drugs or vaccines. Furthermore, the present invention provides a method of inducing an immune response even in immunocompromised patients, patients who are already immune to vaccine viruses, or patients who are receiving antiviral therapy.

Description

[0001] The present invention provides an attenuated virus derived from a modified vaccinia virus Ankara characterized by the loss of the ability to repeatedly replicate in human cell lines. The invention further describes the recombinant virus derived from the virus and the use of the virus or its recombinant as medicine or vaccine. Furthermore, the present invention provides a method for inducing an immune response even in immunocompromised patients, patients who have acquired immunity to the vaccine virus, or patients who are receiving antiviral therapy. Background technique [0002] Modified vaccinia Ankara (MVA) virus refers to vaccinia virus, which is a member of the Orthomyxovirus genus in the Poxviridae family. MVA was obtained by serial passage (CVA) of the Ankara strain of vaccinia virus on chicken embryo fibroblasts (for review see Mayr, A., et al. Infection 3, 6-14 [1975]). Such a long-term passage resulted in an MVA virus with about 31 kb missing in its genome seq...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/09A61K39/275A61K39/285A61K39/39A61K48/00A61P37/04C07K14/16C12N5/10C12N7/00C12N7/01C12N7/02C12N7/04C12N15/39C12N15/863C12P21/02C12R1/93
CPCA61K39/285C12N2710/24143A61K2039/5256A61K2039/545A61K2039/5254A61K2039/53C12N2710/24121A61K48/00C12N2740/16322C12N7/00C12N15/86C07K14/005A61K39/12A61P31/00A61P31/04A61P31/12A61P31/14A61P31/16A61P31/18A61P31/20A61P33/02A61P35/00A61P37/04A61P43/00C12N7/04A61K39/275
Inventor 保罗·查普林保罗·豪利克里斯廷·迈辛格
Owner BAVARIAN NORDIC AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com